Trial Profile
Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Arimoclomol (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Proof of concept; Therapeutic Use
- Acronyms ORARIGAU-01
- Sponsors Orphazyme; Zevra Therapeutics
- 10 Jan 2023 Status changed from active, no longer recruiting to discontinued as COVID-19 pandemic made it impossible to assess the trial objective.
- 17 Nov 2021 Planned End Date changed from 1 Jun 2021 to 9 Dec 2021.
- 29 Jun 2020 Results presented in a CytRx Corporation Media Release.